Abstract
Introduction Recent studies show a growing body of evidence suggesting that users of cannabis have consistently higher prevalence rates of depressive disorders in comparison to non-users. Besides, it can be used as a highly effective treatment for depression and other mood disorders.
Methods A study with a cross-sectional design was conducted with data from respondents aged 25-64 who participated in the 2018 Behavioral Risk Factor Surveillance System (BRFSS) survey. The population was assessed for the baseline characteristics, followed by a bivariate analysis, a multivariate logistic regression to control any confounders, and assess the association between the use of cannabis and depression.
Results The sample included 57,757 individuals. The unadjusted binary logistic regression indicated that those who use cannabis are 93% more likely (OR: 1.93) to have a diagnosis of depression. On the other hand, the adjusted analysis indicated that those who use cannabis are 78% more likely (OR: 1.78) to have a diagnosis of depression. Other variables including participants under the age of 45 years were significantly associated with the diagnosis of depression (OR: 1.35). Moreover, participants with an education without a high school diploma (OR: 0.54), and those having a full-time commitment (OR: 0.37) were significantly less likely to have a diagnosis of depression.
Conclusion Findings suggest that selected U.S. participants who use cannabis have an increased risk to report depression. Furthermore, factors such as age, level of education, and a person’s time commitment status were found to have a significant influence on whether a diagnosis of depression is present.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by The American University of Antigua College of Medicine
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
2018 Behavioral Risk Factor Surveillance System https://www.cdc.gov/brfss/index.html
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Other Authors Joseph Oleary, Email: joleary721{at}gmail.com, Phone: +1 (925) 818-5110, Harsh Bhatt, Email: harshhbhatt35{at}gmail.com, Vira Nadraga, Email: Virun4ik{at}gmail.com
Data Availability
All data produced in the present study are available upon request to the authors
